PharmaTher Faces FDA Setback for Ketamine Drug

PharmaTher Holdings Ltd (TSE:PHRM) has released an update.

PharmaTher Holdings Ltd. announced that the FDA has issued a complete response letter for its ketamine drug application, citing minor deficiencies that need to be addressed. The company is working with its partners to resolve these issues and aims to tackle the ketamine shortage in the U.S. by adhering to FDA guidelines. Despite the setback, PharmaTher remains committed to providing FDA-approved ketamine solutions, especially as compounded versions flood the market without approval.

For further insights into TSE:PHRM stock, check out TipRanks’ Stock Analysis page.